25025
Mário Oliveira
Bibliografia
1. Chugh S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation a
global burden of disease 2010 study. Circulation. 2014;129:837‑847
2. Bonhorst D, Mendes M, Adragão P et al. Prevalência de fibrilhação auricular na população
portuguesa com 40 ou mais anos. Estudo FAMA. Rev Port Cardiol. 2010; 29: 331‑350
3. Magnani JW, Rienstra M, Lin H et al. Atrial fibrillation: current knowledge and future
directions in epidemiology and genomics. Circulation. 2011; 124: 1982– 1993
4. Weijs B, Pisters R, Haest RJ et al. Patients originally diagnosed with idiopathic atrial fibrillation
more often suffer from insidious coronary artery disease compared to healthy sinus rhythm
controls. Heart Rhythm. 2012;9:1923‑9
5. Lubitz S, Benjamin E, Ellinor PT. Atrial fibrillation in congestive heart filure. Heart Fail Clin.
2010; 6: 187–200
6. Zimerman LI FG, Martinelli Filho M, Grupi C, et al. Diretrizes brasileiras de fibrilação atrial.
Arq Bras Cardiol. 2009;92:1‑39
7. A. John Camm, Gregory Y.H. Lip, Raffaele De Caterina, et al. Eur Heart 2012 focused update
of the ESC Guidelines for the management of atrial fibrillation. 2012; 33:2719–2747 (versão
em português: Cândida Fonseca, Mário Oliveira. Recomendações para o tratamento de
doentes com fibrilhação auricular 2012)
8. Francisco Darrieux, Maurício Scanavacca. Fibrilação Atrial ‑ Novas Drogas Antiarrítmicas:
Dofetilida, Ibutilida e Azimilida. Relampa, 1999 12: 194‑200
9. Naccarelli GV, Wolbrette DL, Khan M, et al. Old and new antiarrhythmic drugs for converting
and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
Am J Cardiol. 2003;91:15‑26
10. Joseph S. Alpert, Hugh Calkins, Joaquin E. Cigarroa, et al. 2014 AHA/ACC/HRS Guideline
for the Management of Patients With Atrial Fibrillation: Executive Summary. JACC. 2014;
64,:2246 – 80
11. Peter Zimetbaum. Antiarrhythmic Drug Therapy for Atrial Fibrillation. Circulation. 2012;
125:381‑389
12. Stefan Hohnloser, Harry Crijns, Martin van Eickels, et al for the ATHENA Investigators.
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation. N Engl J Med. 2009;
360:668‑678
13. Naccarelli GV, Wolbrette DL, Samii S, et al. A review of the appropriate and inappropriate
use of dronedarone: lessons learned from controlled studies and regulatory submission. J
Cardiovasc Pharmacol Ther. 2010; 15(4 Suppl):S24‑30.
14. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high‑risk permanent atrial
fibrillation. New Engl J Med. 2011; 365:2268‑76
